NEW YORK, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Inspire Medical Systems, Inc. (NYSE: INSP) and certain of the Company’s senior executives for securities fraud after a significant stock drop resulting from the potential violations of the federal securities laws. If you invested in Inspire, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/inspire-medical- ...

Core Viewpoint - Iridex Corporation, a leader in laser-based medical systems for ophthalmology, will participate in the Sidoti Year-End Virtual Investor Conference on December 11, 2025 [1][2]. Company Overview - Iridex Corporation specializes in developing, manufacturing, and marketing innovative laser-based medical systems, including capital equipment and consumable probes for the ophthalmology market [3]. - The company's proprietary MicroPulse technology provides effective laser treatment while minimizing tissue damage, making it a safe option for treating sight-threatening eye conditions [3]. - Iridex's product line is utilized for treating glaucoma, diabetic macular edema (DME), and other retinal diseases, with sales occurring in the U.S. through a direct sales force and internationally via independent distributors in over 100 countries [3].

Core Insights - Edwards Lifesciences is a leading company in the medical technology sector, focusing on heart valve therapies and critical care monitoring, particularly for structural heart diseases like aortic stenosis and mitral regurgitation [1] Company Performance - On December 4, 2025, BTIG upgraded Edwards Lifesciences to a "Buy" recommendation, with the stock priced at $85.78, reflecting confidence in the company's sustainable growth strategy and strong market position [2] - BTIG also raised the price target for Edwards Lifesciences from $100 to $103, indicating optimism about the company's ability to leverage emerging opportunities and expand its market presence [3] - The stock has shown resilience, currently priced at $85.78, with a recent increase of 2.14%, and has fluctuated between $65.94 and $87.40 over the past year, demonstrating stable performance [4] Market Position - Edwards Lifesciences has a market capitalization of approximately $50.37 billion, highlighting its significant presence in the medical technology industry [5] - The company has a trading volume of 2,385,439 shares, indicating strong investor interest and solidifying its leadership in heart valve therapies and critical care solutions [5]

Core Thesis - Johnson & Johnson (J&J) is viewed positively due to its diversified business model, strong financials, and consistent dividend growth, making it an attractive investment opportunity [1][4]. Business Overview - J&J operates in three major divisions: pharmaceuticals, medical devices, and consumer health products, with pharmaceuticals being the largest growth driver [2]. - The company’s consumer health brands, such as Tylenol and Band-Aid, provide stability and relevance in everyday life, ensuring recurring demand and resilient cash flows [2]. Financial Performance - J&J's revenues increased from $70 billion in 2015 to nearly $89 billion projected for 2024, with operating income exceeding $61 billion [3]. - The company maintains a conservative payout ratio of around 55–60%, supporting its status as a Dividend King with 62 consecutive years of dividend increases [3]. Investment Metrics - J&J scores above 90 on the MaxDividends framework, indicating strong stability across sales growth, profit growth, net income resilience, payout safety, and low leverage [4]. - The stock has a moderate dividend yield of 2.8% and steady growth of approximately 6%, with valuation metrics suggesting it is slightly undervalued compared to peers [4]. Recent Performance - Since a previous bullish thesis in January 2025, J&J's stock price has appreciated by approximately 40.42%, reflecting strong fundamentals and continued investor confidence [5].

Core Viewpoint - The handheld surgical retractor market is projected to reach $350 million by 2031, with a compound annual growth rate (CAGR) of 3.18% in the coming years [3]. Market Overview - The global market for handheld surgical retractors is characterized by stable demand for traditional instruments and technological upgrades leading to structural optimization [4]. - The top 14 manufacturers hold approximately 82% of the market share, with key players including Johnson & Johnson, Medtronic plc, and Becton, Dickinson & Co. [8]. Industry Development Trends - The industry is experiencing a shift from standardized stainless steel tools to high-performance, low-damage, and specialized products [4]. - The demand for handheld retractors is driven by the increasing volume of surgical procedures, particularly in general surgery, orthopedics, and neurosurgery [9]. - There is a growing trend towards disposable handheld retractors and replaceable blade kits in specific departments, driven by infection control and efficiency needs [4][9]. Upstream Supply Chain - The upstream supply chain consists of medical-grade metals, precision processing equipment, surface treatment technologies, and sterile packaging materials [10]. - Key raw materials include medical-grade stainless steel and titanium alloys, which are crucial for the retractor's durability and safety [10]. Midstream Manufacturing - The midstream sector focuses on instrument design, precision manufacturing, quality verification, and brand management [11]. - Midstream companies are adapting to various surgical scenarios by developing multiple blade shapes and handle structures [11][12]. Downstream Applications - Handheld surgical retractors are widely used across various surgical departments, including general surgery, orthopedics, and emergency trauma [13]. - The demand structure is evolving towards a combination of general high-volume needs and specialized, refined retractors for specific surgical applications [13].

Market Overview - The market is currently described as "sideways with a lot of chop," indicating increased volatility since October, with a slight upward tilt [4][5]. - There is uncertainty regarding the next market move, influenced by factors such as AI spending and changing liquidity dynamics [5]. AI and Technology Sector - The credit market is beginning to show concern over the spending on AI technologies, with credit default swaps for companies like Oracle rising significantly, indicating increased perceived risk [6][9]. - Companies like Oracle and Meta are experiencing declining free cash flows, raising questions about the sustainability of their AI investments [9][10]. - The market is starting to question the viability of major tech companies, suggesting a potential shift in focus away from the "Magnificent Seven" tech stocks [12][58]. Healthcare Sector - The healthcare sector is highlighted as a promising area for investment, with potential for significant gains from AI applications [13][19]. - Specific companies of interest include UnitedHealth, Zoetis, Illumina, and Intuitive Surgical, which are seen as having strong growth prospects [16][18][20]. - The potential for AI to transform healthcare, particularly in early cancer detection, is emphasized as a key opportunity [19]. Bond Market Insights - Despite Fed rate cuts, long-term bond yields have not decreased significantly, with the 30-year rate remaining around 4.75% [32][34]. - The flattening yield curve suggests that investors may prefer short-term treasury bills over longer-duration bonds, indicating a lack of confidence in long-term rates [35][39]. - The relationship between U.S. and Japanese interest rates is highlighted, with rising rates in Japan potentially influencing U.S. rates upward [48][57]. Broader Market Implications - The current market environment suggests a need for investors to consider sectors beyond AI and big tech, as historical leaders may not dominate future market cycles [58]. - The dynamics of credit spreads and global interest rates are crucial for understanding market movements and potential investment strategies [56].

NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of DexCom, Inc. (NASDAQ:DXCM) and Wildermuth Fund (NASDAQ:WEFCX, NASDAQ:WESFX. NASDAQ:WEIFX). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided. DexCom, Inc. (NASDAQ:DXCM) Class Period: ...

Financial Data and Key Metrics Changes - Consolidated revenues increased by 4.6% year over year, reaching a record of $1.065 billion, with organic growth of 3.4% [8][18] - Non-GAAP earnings per share (EPS) grew by 11% to $1.15, marking the eighth consecutive quarter of beating consensus earnings expectations [5][18] - Free cash flow for Q4 was strong at $150 million, with a total fiscal year repurchase of nearly $300 million, representing about two-thirds of free cash flow [5][19] Business Line Data and Key Metrics Changes - CooperVision reported revenue of $710 million, up 4.9% year over year, with organic growth of 3.2%, driven by improved availability of MyDay lenses [9][10] - CooperSurgical achieved quarterly revenue of $356 million, up 4% or 3.9% organically, with growth in fertility and surgical segments [14][15] Market Data and Key Metrics Changes - The Americas region grew by 5%, while EMEA grew by 3%, slightly below expectations due to market weakness in some countries [10][14] - Asia-Pacific was flat, primarily due to a 28% decline in China, attributed to weakness in low-margin e-commerce channels [10][12] Company Strategy and Development Direction - The company is focused on delivering consistent market share gains for CooperVision, with an emphasis on the MyDay Premium Daily Silicone Hydrogel Lens portfolio [4][6] - A formal strategic review has been initiated to explore opportunities for unlocking long-term shareholder value, including potential separation of business units [8][31][54] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about fiscal 2026, expecting strong revenue growth driven by MyDay sales and new private label contracts [39][60] - The company anticipates a conservative approach to guidance, particularly in the fertility segment, while remaining optimistic about long-term growth prospects [15][60] Other Important Information - The board authorized an increase in the share repurchase plan to $2 billion, reinforcing the commitment to returning capital to shareholders [6][19] - The company has successfully remediated material weaknesses related to IT controls from fiscal 2024 [24] Q&A Session Summary Question: Clariti product line performance - Clariti was down a couple of percent this quarter, approaching $400 million in annualized revenue, with ongoing efforts to reposition the product line [25][26] Question: Strategic review process - A strategic review is underway, with updates expected in the next earnings call, focusing on driving long-term shareholder value [30][31] Question: Market growth assumptions - The market is expected to grow at 4%-5% in fiscal 2026, with pricing power remaining stable [33][34] Question: Asia-Pacific market dynamics - The company faced challenges in Asia-Pacific, particularly in low-margin e-commerce channels, but expects less detriment in fiscal 2026 [37][38] Question: Free cash flow outlook - The increase in free cash flow is attributed to consistent performance and reduced capital expenditures, with expectations of over $2.2 billion in free cash flow from fiscal 2026 to 2028 [23][42] Question: Paragard product expectations - Guidance for Paragard includes conservatism due to potential competitive launches, with expectations for flat to low single-digit growth [55] Question: Pipeline and product launches - The company is excited about upcoming product launches, including MyDay and MiSight, which are expected to drive growth [58][59]

IRVINE, Calif.--(BUSINESS WIRE)--Nihon Kohden, a global leader in neurodiagnostic technology, will showcase its integrated EEG portfolio at the American Epilepsy Society (AES) 2025 Annual Meeting, held December 5–9 in Atlanta. Attendees are invited to Booth #725 to explore solutions shaped through extensive collaboration with the clinicians who use them—bringing together mobility, connectivity and performance to advance neurological care. With a history of advancing EEG technology that predates. ...

Core Insights - Profound Medical Corp. announced that Dr. Pejman Ghanouni received the Cum Laude award for his presentation on the CAPTAIN trial comparing MRI-guided TULSA Procedure with robotic radical prostatectomy at the RSNA Annual Meeting 2025, highlighting the significance of this recognition in the medical community [1][2][3] Company Overview - Profound Medical Corp. is a commercial-stage medical device company focused on developing AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue [5][6] - The company is commercializing the TULSA-PRO system, which utilizes real-time MRI and AI-enhanced planning for precise prostate tissue ablation, aiming to become a mainstream treatment for various prostate conditions [6][7] TULSA Procedure Details - The TULSA Procedure is a non-invasive treatment that uses robotically controlled ultrasound to ablate prostate tissue while preserving surrounding structures, offering advantages such as no blood loss, no overnight hospital stay, and quicker recovery times compared to traditional surgical methods [3][7] - The procedure is designed to be performed in a single session, taking a few hours, and is suitable for a wide range of prostate shapes and sizes [7] CAPTAIN Trial Insights - The CAPTAIN trial is a multi-center randomized controlled study comparing the safety and efficacy of the TULSA Procedure with robotic radical prostatectomy in men with organ-confined, intermediate-risk prostate cancer, with 210 patients randomized as of January 2025 [4] - The trial's results indicate that patients undergoing the TULSA Procedure experience significantly shorter recovery times, with many feeling back to normal the day after the procedure, compared to an average of three weeks for robotic surgery patients [3][4] Recognition and Awards - Dr. Ghanouni's presentation was one of only six to receive the Cum Laude award at RSNA 2025, representing the top 5% of scientific posters, underscoring the quality and impact of the research presented [2][3] - Additionally, Dr. Satoru Takahashi received a Certificate of Merit for his work on TULSA, further validating the procedure's emerging role in prostate cancer treatment [3]